FDA approves Boostrix for tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed in third trimester of pregnancy
GSK announced that the FDA has approved Boostrix (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed [Tdap]) for immunisation during the third trimester of pregnancy to help prevent pertussis (whooping cough) in infants less than two months of age
Boostrix is indicated in the US for: Active booster immunisation against tetanus, diphtheria and pertussis in individuals aged 10 years and older, and: Immunisation during the third trimester of pregnancy to help prevent pertussis (whooping cough) in infants less than two months of age.
According to the CDC, the Tdap vaccination given during pregnancy provides the best protection to infants against whooping cough. Vaccination passes protective antibodies to babies before birth to protect them in their first months of life.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.